Insider Buying: Roivant Sciences Ltd. (NASDAQ:ROIV) Director Acquires $336,900,200.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Sciences Ltd. Roivant purchased 16,845,010 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was bought at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the acquisition, the director now directly owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $11.15 on Friday. The firm has a market capitalization of $8.12 billion, a P/E ratio of 1.97 and a beta of 1.27. The business’s 50-day moving average is $11.79 and its 200 day moving average is $11.58. Roivant Sciences Ltd. has a 1 year low of $9.69 and a 1 year high of $13.06.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.93.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nordea Investment Management AB raised its position in Roivant Sciences by 22.5% during the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock valued at $3,306,000 after acquiring an additional 52,031 shares in the last quarter. Clearbridge Investments LLC raised its holdings in Roivant Sciences by 51.3% in the 2nd quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company’s stock worth $19,666,000 after purchasing an additional 630,712 shares during the period. Point72 Asset Management L.P. boosted its position in Roivant Sciences by 40.1% during the second quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company’s stock worth $6,840,000 after purchasing an additional 185,226 shares in the last quarter. Exchange Traded Concepts LLC acquired a new stake in Roivant Sciences in the third quarter valued at approximately $2,267,000. Finally, TOMS Capital Investment Management LP purchased a new stake in shares of Roivant Sciences in the third quarter valued at approximately $46,333,000. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.